AFP-targeting therapies have mainly utilized chimeric antigen receptor (CAR) T-cell therapy, which involves the use of genetically modified T cells engineered to recognize target antigens expressed on tumor cells and elicit an immune response (58). Here, AFP is linked to neoplasm.